Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases

Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model

“… 45 , 46 However, this is based primarily on passive surveillance, and active surveillance programs indicate an incidence of neurotropic disease after YF vaccination occurring at rates as high as 1 in 10,000 to 1 in 71,000 vaccinations. 47 , 48 , 49 Transmission of virologically confirmed vaccine-derived YFV has occurred through blood transfusions, 50 and transmission to infants through breastfeeding has resulted in meningoencephalitis and seizures—leading to formal contraindication to live YF vaccination among breastfeeding mothers. 51 , 52 , 53 , 54 YFV-17D vaccination may also cause multiple organ failure, described as YEL-AVD, a syndrome closely resembling wild-type YF.…”

Yellow fever in Brazil: Reflections on vaccine safety and effectiveness

“…Estudo de coorte retrospectivo, desenvolvido nos Estados Unidos, com dados de 263.979 pacientes entre 2004 e 2019, observou que em menos de 1% desta amostra havia condições de predisposição à imunossupressão. Ademais, foram identificados quatro casos não fatais de doenças neurotrópicas associadas à vacina contra febre amarela (YEL-AND) e nenhuma viscerotrópica (YEL-AVD), o que levou à conclusão que o risco de desenvolver estas enfermidades pós-vacinação permanece raro (LEDLIE et al, 2022).…”